Amicus Therapeutics receives U.S. approval for Fabry disease drug



U.S. health regulators on Friday approved Amicus Therapeutics’ Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.





Source link

Be the first to comment

Leave a Reply

Your email address will not be published.


*